

# Marina Magrey

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5516087/marina-magrey-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26

papers

865

citations

11

h-index

29

g-index

31

ext. papers

1,202

ext. citations

7.1

avg, IF

4.14

L-index

#	Paper	IF	Citations
26	2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1521-1537	9.5	261
25	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 5-32	9.5	178
24	New insights into synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome. <i>Current Rheumatology Reports</i> , <b>2009</b> , 11, 329-33	4.9	66
23	A unifying biologic explanation for "high-sensitivity" C-reactive protein and "low-grade" inflammation. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 442-6	4.7	49
22	Osteoporosis in ankylosing spondylitis. <i>Current Rheumatology Reports</i> , <b>2010</b> , 12, 332-6	4.9	45
21	Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. <i>Lancet, The</i> , <b>2018</b> , 392, 134-144	4.0	42
20	Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1227-1239	59.2	41
19	Anti-glomerular basement membrane antibody disease treated with rituximab: A case-based review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2013</b> , 42, 567-72	5.3	40
18	Screening and treatment of osteoporosis after hip fracture: comparison of sex and race. <i>Journal of Clinical Densitometry</i> , <b>2014</b> , 17, 479-83	3.5	34
17	Utility of DXA scanning and risk factors for osteoporosis in ankylosing spondylitis-A prospective study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 46, 88-94	5.3	22
16	Sacroiliitis mimics: a case report and review of the literature. <i>BMC Musculoskeletal Disorders</i> , <b>2017</b> , 18, 170	2.8	16
15	Recognizing Axial Spondyloarthritis: A Guide for Primary Care. <i>Mayo Clinic Proceedings</i> , <b>2020</b> , 95, 2499-2508	5.0	11
14	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	11
13	Primary Sjogren's syndrome with anticentromere antibodies--a clinically distinct subset. <i>Clinical Rheumatology</i> , <b>2010</b> , 29, 789-91	3.9	10
12	Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia. <i>Drug, Healthcare and Patient Safety</i> , <b>2016</b> , 8, 13-23	1.6	10
11	Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	9
10	Measuring outcomes in ankylosing spondylitis: pearls and pitfalls. <i>Current Opinion in Rheumatology</i> , <b>2019</b> , 31, 109-117	5.3	5

9	A Pilot Study to Assess the Feasibility of a Web-Based Survey to Examine Patient-Reported Symptoms and Satisfaction in Patients with Ankylosing Spondylitis Receiving Secukinumab. <i>Drugs - Real World Outcomes</i> , <b>2019</b> , 6, 83-91	2.2	4
8	Understanding Barriers in the Pathway to Diagnosis of Ankylosing Spondylitis: Results From a US Survey of 1690 Physicians From 10 Specialties. <i>ACR Open Rheumatology</i> , <b>2020</b> , 2, 616-626	3.5	3
7	Evaluation of the Feasibility of a Web-Based Survey to Assess Patient-Reported Symptom Improvement and Treatment Satisfaction Among Patients with Psoriatic Arthritis Receiving Secukinumab. <i>Clinical Drug Investigation</i> , <b>2019</b> , 39, 1205-1212	3.2	3
6	Clinical Manifestations and Diagnosis of Axial Spondyloarthritis. <i>Journal of Clinical Rheumatology</i> , <b>2021</b> , 27, e547-e560	1.1	3
5	Worldwide Differences in Clinical Phenotype of Axial Spondyloarthritis. <i>Current Rheumatology Reports</i> , <b>2021</b> , 23, 76	4.9	2
4	Use of upadacitinib in the treatment of psoriatic arthritis. <i>Immunotherapy</i> , <b>2021</b> , 13, 1549-1554	3.8	0
3	Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. <i>RMD Open</i> , <b>2022</b> , 8, e002253	5.9	0
2	HLA-B27 Homozygosity and Clinical Features of Ankylosing Spondylitis. <i>Current Rheumatology Reports</i> , <b>2010</b> , 12, 309-310	4.9	
1	Nonradiographic axial spondyloarthritis: expanding the spectrum of an old disease: A narrative review.. <i>Medicine (United States)</i> , <b>2022</b> , 101, e29063	1.8	